The unparalleled bone and heart benefits of vitamin K2 MK-7 have opened doors to mass market consumers. More and more K2 products are being launched, with companies and marketers looking to gain first-mover advantage.
The roundtable discussion and Q&A will cover the following:
- K2 science
- market opportunity
- commercial risks
- formulation
- galenics
- stability and quality
- analysis.
K2 is ready for mass markets. Join Kappa Bioscience to learn how to profit from the enormous potential of vitamin K2 MK-7.
Speakers
- Egil Greve President & CEO at Kappa Bioscience
- Morgan Laloux Business Development Manager Health and Nutrition Southern Europe at Capsugel
- Scott Colbourne Business Manager NSW, Food & Pharmaceutical at ALS Pharmaceutical Australia
- Jim Bornhold Executive VP of Nutraceuticals at Chemroy Canada
- Bjarne Bloch Medical Advisor at Orkla Care A/S
- Jörg Büttinghaus VP Sales & Marketing at Kappa Bioscience
Interested in attending the event: The Experts Discuss: Successful Product Launches, click here to register
